ClinicalTrials.gg
RecruitingNCT07524452Updated Apr 13, 2026

Becotatug Vedotin (MRG003) in Combination With PD-1 Inhibitor Versus PD-1 Inhibitor for the Treatment of EGFR-positive, CPS≥1 Resectable Locally Advanced Head and Neck Squamous Cell Carcinoma

A Phase 3 interventional study of Neoadjuvant and Adjuvant Becotatug Vedotin and Neoadjuvant and Adjuvant Immunotherapy in Locally Advanced Head and Neck Squamous Cell Carcinoma, sponsored by Ming-Yuan Chen. Recruiting at 1 site in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-04-13.

Sponsored by Ming-Yuan Chen · Phase 3, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Feb 2026; still recruiting 9 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
430
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 16 studies testing becotatug vedotin in Squamous Cell Carcinoma of Head and Neck — 15 open to participants now, 15 under way, 2 of them phase 3. becotatug vedotin · Squamous Cell Carcinoma of Head and Neck.

Planned enrollment
Largest of 16
430 · median 52
Started
2026
with 11 others
Phase 3
2 of 16
2 open now
Primary completion
2031-02
later than 14 of 14 live
Registered
5th of 16
by date
Lead sponsor
1 of 16
Ming-Yuan Chen

Among the 16 studies testing becotatug vedotin in Squamous Cell Carcinoma of Head and Neck, this one has the largest planned enrollment, is one of 12 that started in 2026, is one of 2 in phase 3, reaches primary completion later than 14 of the 14 other live ones, and was the 5th registered.

Squamous Cell Carcinoma of Head and Neck

2,022 studies on the registry are indexed under Squamous Cell Carcinoma of Head and Neck; 573 are open to participants now.

Browse Squamous Cell Carcinoma of Head and Neck studies →

Open to participants now

15 of the 16 studies testing becotatug vedotin in Squamous Cell Carcinoma of Head and Neck are open now, in 1 country. Recruiting first, the newest first:

9 more — sign in →

By country, each count listing its studies:

All 15 open studies →

Where they have run

About becotatug vedotin

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 434 Squamous Cell Carcinoma of Head and Neck studies recruiting now, 310 (71%) set no upper age limit and 87 (20%) stop at 75 or younger; 5 take children under 18; 13 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 16 studies testing becotatug vedotin in Squamous Cell Carcinoma of Head and Neck, or all of them as a file.
02

Study summary

This study is a randomized, open-label, multicenter phase III trial designed to systematically evaluate the efficacy and safety of perioperative neoadjuvant and adjuvant therapy with Becotatug vedotin in combination with PD-1 inhibitor versus PD-1 inhibitor alone in patients with EGFR-positive, CPS ≥ 1 resectable locally advanced head and neck squamous cell carcinoma .

03

Conditions studied

  • Locally Advanced Head and Neck Squamous Cell Carcinoma

Keywords

  • Resectabl locally advanced head and neck squamous cell carcinoma
  • Becotatug Vedotin
  • perioperative neoadjuvant and adjuvant therapy
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Voluntarily sign the form;
  2. Untreated, confirmed head and neck squamous cell carcinoma (oral cavity, oropharynx, hypopharynx, or larynx), EGFR-positive, CPS ≥ 1, with clinical stage (AJCC 8th edition): p16-positive oropharynx: Stage III (T4N0-2M0); p16-negative oropharynx: Stage III or IVA; larynx/hypopharynx/oral cavity: Stage III or IVA;
  3. Eligible for curative-intent surgery as determined by the surgeon;
  4. Age: 18 to 75 years;
  5. performance status 0-1;
  6. greater than 6 months;
  7. At least one per 1.1;
  8. Adequate organ function, based on meeting all of the following criteria (no receipt of blood components or hematopoietic growth factors within 14 days prior to testing): ≥ 90 g/L; ≥ 1.5 × 10⁹/L; count ≥ 100 × 10⁹/L; serum albumin ≥ 28 g/L; total ≤ 1.5 × (ULN); and AST ≤ 2.5 × ULN; serum creatinine ≤ 1.5 × ULN, with ≥ 50 mL/min; and international normalized ratio (INR) ≤ 1.5 × ULN (patients receiving a stable dose of anticoagulant therapy, such as low molecular weight heparin or warfarin, may be enrolled if INR is within the expected therapeutic range for the anticoagulant). Thyroid-stimulating hormone (TSH) ≤ ULN; if abnormal, T3 and T4 levels should be assessed, and patients with normal T3 and T4 levels may be enrolled;
  9. Baseline (LVEF) ≥ 50% as measured by multigated acquisition (MUGA) scan or echocardiography (ECHO);
  10. Women of must agree to use (e.g., intrauterine device, contraceptive pill, or condom) during the treatment period and for 3 months after the last dose;
  11. Good compliance.

Exclusion criteria

Exclusion Criteria:

  1. Pregnant or breastfeeding women.
  2. History of allergy to inhibitors.
  3. History of other within the past 5 years or at enrollment, with the exception of cured basal cell carcinoma of the skin, carcinoma in situ of the cervix, and thyroid papillary tumors.
  4. Residual toxicity from prior anti-tumor therapy (including immunotherapy, targeted therapy, chemotherapy, or radiotherapy, etc.) other than alopecia, fatigue, and grade 2 hypothyroidism, or laboratory abnormalities greater than grade 1 ( v5.0).
  5. Uncontrolled cardiac conditions or diseases, such as: ① Class II or greater heart failure, ② unstable angina, ③ myocardial infarction within 1 year, and ④ patients with clinically significant ventricular arrhythmias requiring intervention.
  6. Grade ≥ 2 peripheral neuropathy (per CTCAE v5.0).
  7. Pulmonary embolism or deep vein thrombosis within 3 months prior to enrollment (excluding catheter-related thrombosis from infusion ports or PICC lines).
  8. Active bleeding, history of coagulation disorders, or patients receiving coumarin anticoagulant therapy.
  9. Known to any component or of vibecotamab (citric acid monohydrate, sodium citrate dihydrate, trehalose dihydrate, sodium chloride, and polysorbate 80), or known grade ≥ 3 hypersensitivity reaction to other prior anti-EGFR agents (including drugs) or other monoclonal antibodies.
  10. Receipt of any of the following treatments:

    ① Any investigational drug prior to the first dose of the current study drug.

    ② Concurrent participation in another clinical study, unless it is an observational (non-interventional) clinical study or during the follow-up period.

    ③ Use of systemic (more than 10 mg of prednisone or equivalent per day) or other agents within 2 weeks prior to the first dose of study drug, except for the use of corticosteroids for localized inflammation, prevention of allergies, or nausea and vomiting. In the absence of active disease, inhaled or topical steroids and adrenal corticosteroid replacement doses greater than 10 mg prednisone equivalent per day are permitted.

    ④ Administration of within 4 weeks prior to the first dose of study drug.

    ⑤ Major surgery or severe trauma within 4 weeks prior to the first dose of study drug.

  11. Severe infection (greater than grade 2 per CTCAE), such as severe pneumonia requiring hospitalization, bacteremia, or infectious complications, occurring within 4 weeks prior to the first dose of study drug; baseline chest imaging indicating active pulmonary inflammation or signs and symptoms of infection within 2 weeks prior to the first dose of study drug, or indicating the need for oral or intravenous antibiotic therapy (excluding prophylactic antibiotic use).
  12. History of or concurrent severe with respiratory failure, severe pulmonary insufficiency, symptomatic bronchospasm, etc.
  13. History of active autoimmune diseases or syndromes (including but not limited to interstitial pneumonia, colitis, hepatitis, hypophysitis, vasculitis, nephritis, hyperthyroidism, and hypothyroidism). Patients with vitiligo that did not require any intervention in adulthood, or childhood asthma/allergy that has resolved, are not excluded.
  14. History of immunodeficiency, including -positive status or other acquired/congenital immunodeficiency diseases, or history of organ transplantation or bone marrow transplantation.
  15. Patients with active tuberculosis infection by history or CT findings, or history of active tuberculosis infection within 1 year prior to enrollment, or history of active tuberculosis infection more than 1 year prior without receiving formal treatment.
  16. Active (HBV DNA ≥ 2,000 IU/mL or 10,000 copies/mL) or (positive HCV antibody test with HCV RNA above the lower limit of detection).
  17. Uncontrolled pleural, peritoneal, pelvic, or pericardial effusion requiring drainage ≥ 1 time per month.
  18. Known history of substance abuse, alcoholism, or drug use.
  19. Inappropriate for inclusion based on the investigator's judgment.
Terms in these criteria, in plain language(33)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
430 participants (estimated)

Study arms

  • Experimental
    Becotatug vedotin plus pucotenlimab arm

    Patients receive Becotatug vedotin combined with pucotenlimab as neoadjuvant treatment prior to surgical resection and as adjuvant treatment after radiotherapy.

    Drug: Neoadjuvant and Adjuvant Becotatug Vedotin · Drug: Neoadjuvant and Adjuvant Immunotherapy · Procedure: Surgery · Radiation: Adjuvant Radiotherapy · Drug: Adjuvant Cisplatin

  • Active comparator
    pucotenlimab arm

    Patients receive pucotenlimab as neoadjuvant treatment prior to surgical resection and as adjuvant duiring and after radiotherapy.

    Drug: Neoadjuvant and Adjuvant Immunotherapy · Procedure: Surgery · Radiation: Adjuvant Radiotherapy · Drug: Adjuvant Cisplatin

Interventions

  • DrugNeoadjuvant and Adjuvant Becotatug Vedotin

    Drug page: Becotatug vedotinStudies of Becotatug vedotinBecotatug vedotin pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Neoadjuvant therapy with Becotatug Vedotin (Day 1, Q3W, 2 cycles); Adjuvant therapy after radiotherapy with Becotatug Vedotin ( Day 1, Q3W, for a total of 12 cycles).

  • DrugNeoadjuvant and Adjuvant Immunotherapy

    Neoadjuvant immunotherapy with pucotenlimab (200mg, Day 1, Q3W, 2 cycles); Adjuvant immunotherapy duiring and after radiotherapy with pucotenlimab (200mg, Day 1, Q3W, for a total of 15 cycles).

  • ProcedureSurgery

    Radical surgery performed 3-4 weeks after neoadjuvant therapy, following a re-evaluation of surgical indications by the surgeon.

  • RadiationAdjuvant Radiotherapy

    Radiotherapy is initiated 4-6 weeks after surgery. For the low-risk group, a total dose of 60 Gy in 30 fractions is delivered using intensity-modulated radiation therapy (IMRT). For the high-risk group, 66 Gy in 33 fractions is prescribed, or 70 Gy in 35 fractions for residual lesions, also using IMRT.

  • DrugCisplatinStudies of CisplatinCisplatin pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    High-risk group:Cisplatin 100 mg/m² is administered via intravenous infusion on Day 1 of every 21-day cycle during radiotherapy, for a total of 3 cycles.

06

What researchers measure

Primary outcomes

  1. Event-Free Survival Rate (EFS)

    Defined as the time from randomization to the first occurrence of disease progression, relapse, or death from any cause.

    Time frame: 3 years

Secondary outcomes

  1. Overall Survival (OS)

    Defined as the time interval from randomization to death due to any cause.

    Time frame: 3 years

  2. Distant Metastasis-Free Survival (DMFS)

    Defined as the time interval from randomisation to the date of first distant metastases.

    Time frame: 3 years

  3. Locoregional Relapse-Free Survival (LRRFS)

    Defined as the time from randomisation to the date of first locoregional relapse.

    Time frame: 3 years

  4. Objective Response Rate (ORR)

    The proportion of patients achieving an objective response (complete response and partial response) by imaging assessment after the completion of neoadjuvant therapy, prior to surgery.

    Time frame: After the completion of neoadjuvant therapy, prior to surgery.

  5. Disease Control Rate (DCR)

    The proportion of patients achieving predefined efficacy evaluation criteria (complete response, partial response, and stable disease) by imaging assessment after the completion of neoadjuvant therapy, prior to surgery.

    Time frame: After the completion of neoadjuvant therapy, prior to surgery.

  6. Major Pathologic Response Rate (mPR):

    The proportion of patients with less than 10% residual viable tumor cells in the tumor bed, assessed at 1 week post-surgery.

    Time frame: 1 week post-surgery

  7. Pathologic Complete Response Rate (pCR)

    The proportion of patients with no microscopic residual viable tumor cells, assessed at 1 week post-surgery.

    Time frame: 1 week post-surgery

  8. Incidence of treatment related acute complications

    The proportion of patients with treatment related acute complications according to NCI-CTC5.0 criteria and RTOG criteria.

    Time frame: up to 1 year

  9. Incidence of treatment related late complications

    The proportion of patients with treatment related late complications according to NCI-CTC5.0 criteria and RTOG criteria.

    Time frame: up to 3 years

  10. Non-Surgery Delay Rate

    The proportion of patients whose surgery is delayed by more than 4 weeks from the planned date, assessed at 8 weeks after two cycles of neoadjuvant therapy.

    Time frame: 8 weeks after two cycles of neoadjuvant therapy

  11. R0 Resection Rate

    The proportion of patients undergoing surgical resection who achieve R0 resection (complete tumor resection with negative histopathological margins), assessed at 1 week post-surgery.

    Time frame: 1 week post-surgery.

  12. General Quality of Life

    Changes from baseline in general patient-reported quality of life were assessed using the EORTC QLQ-C30 . The scores range from 0 to 100, with higher scores indicating a better quality of life outcome and lower scores indicating worse symptoms or functions.

    Time frame: Baseline, week 4 (post-neoadjuvant), week 6 (preoperative), week 8 (postoperative), week 10 (pre-radiotherapy), week 17 (post-radiotherapy), every 2 cycles of adjuvant therapy (each cycle is 21 days), and at each follow-up, up to 3 years

  13. Head and Neck Cancer-Specific Quality of Life

    Changes from baseline in head and neck cancer-specific quality of life assessed by EORTC QLQ-H\&N35. The scores range from 0 to 100, with higher scores indicating a better quality of life outcome and lower scores indicating worse symptoms or functions.

    Time frame: Baseline, week 4 (post-neoadjuvant), week 6 (preoperative), week 8 (postoperative), week 10 (pre-radiotherapy), week 17 (post-radiotherapy), every 2 cycles of adjuvant therapy (each cycle is 21 days), and at each follow-up, up to 3 years.

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Feb 2026 (actual). Primary completion is estimated for Feb 2031, 60 months after the start.

Of 51 non-industry phase 3 interventional studies under Squamous Cell Carcinoma of Head and Neck, half reached primary completion within 95 months of starting (the median), counting those still running; a quarter within 67 and three quarters within 121. This study's planned 60 months is below that.

Counting every sponsor, half of 78 studies reached it within 76 months; a quarter within 38 and three quarters within 117.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 28, 2026
First posted
Apr 13, 2026
StartActual
Feb 6, 2026
Primary completionEst.
Feb 28, 2031
CompletionEst.
Feb 28, 2032
Last update
Apr 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 13, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07524452
Lead sponsor
Ming-Yuan Chen
Responsible party
Ming-Yuan Chen (Professor, Chief physician, Sun Yat-sen University) — Sponsor-investigator
First posted
Apr 13, 2026
Start date
Feb 6, 2026
Primary completion
Feb 28, 2031 (estimated)
Completion
Feb 28, 2032 (estimated)
Last update
Apr 13, 2026

Study contacts

Mingyuan Chen
Contact
chmingy@mail.sysu.edu.cn
+86 18124188280
Rui You
Contact
your5@mail.sysu.edu.cn
+86 13580439820

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Becotatug vedotin

Start the discussion